Leuprone 1-Monatsdepot

Leuprorelin, the active ingredient in Leuprone 1-Monatsdepot, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a 1‑month depot injection for subcutaneous use. It treats hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids, precocious puberty, and hormone‑sensitive breast cancer (off‑label).

GNH USA supplies Leuprone 1-Monatsdepot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leuprone 1-Monatsdepot is a GnRH agonist used in several hormone‑dependent disease areas. - Prostate cancer: lowers testosterone levels to inhibit tumor growth. - Endometriosis: suppresses estrogen production to reduce lesion activity and pain. - Uterine fibroids: decreases ovarian hormone stimulation, leading to fibroid shrinkage. - Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis. - Hormone‑sensitive breast cancer (off‑label): reduces circulating estrogen to limit tumor progression.

Leuprone 1-Monatsdepot may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Injection site reactions: pain, redness, or swelling at the subcutaneous site. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Nausea: occasional upset stomach. - Decreased libido: reduced sexual desire.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat. - Cardiovascular events: hypertension, thromboembolic complications. - Bone mineral density loss: increased risk of osteoporosis with long‑term use. - Tumor flare syndrome: temporary worsening of disease symptoms at treatment start.

Before initiating therapy, several safety considerations are recommended. - Pregnancy: avoid use; safety in pregnancy is unknown. - Breastfeeding: contraindicated; leuprorelin may be excreted in milk. - Cardiovascular disease: assess risk and monitor blood pressure regularly. - Bone health: evaluate baseline bone density and consider supplementation. - Hormone‑sensitive tumors: monitor disease status closely during treatment. - Drug interactions: review concomitant medications for potential interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP450 inducers (e.g., rifampicin) may lower leuprorelin levels. - Concurrent use of long‑acting GnRH antagonists can produce antagonistic hormonal effects.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin) may increase bleeding risk. - Bisphosphonates may compound bone density loss. - Systemic steroids can mask signs of adrenal insufficiency. - Hormonal replacement therapy may counteract leuprorelin’s suppressive action.